In particular, the combination of venetoclax, a Bcl-2 inhibitor that targets the antiapoptosis mechanism of mitochondria, with Ara-C or 5-azacitidine can improve the survival rate of AML patients, suggesting that mitochondria are relevant therapeutic targets for AML [29–32]. This evidence concerns the gene BCL2 and acute myeloid leukemia.